# Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

> **NCT02478164** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 17 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT02478164
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2017-07-08
- **Final completion:** 2018-05-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478164, "Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02478164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*